Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.06
PRGO's Cash-to-Debt is ranked lower than
94% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. PRGO: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
PRGO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.22 Max: 18.37
Current: 0.06
0.01
18.37
Equity-to-Asset 0.50
PRGO's Equity-to-Asset is ranked lower than
67% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. PRGO: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
PRGO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.5 Max: 0.75
Current: 0.5
0.34
0.75
Piotroski F-Score: 4
Altman Z-Score: 0.78
Beneish M-Score: -3.26
WACC vs ROIC
4.77%
-8.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -29.67
PRGO's Operating Margin % is ranked lower than
83% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. PRGO: -29.67 )
Ranked among companies with meaningful Operating Margin % only.
PRGO' s Operating Margin % Range Over the Past 10 Years
Min: -29.67  Med: 14.39 Max: 19.18
Current: -29.67
-29.67
19.18
Net Margin % -26.62
PRGO's Net Margin % is ranked lower than
82% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PRGO: -26.62 )
Ranked among companies with meaningful Net Margin % only.
PRGO' s Net Margin % Range Over the Past 10 Years
Min: -26.62  Med: 7.52 Max: 12.66
Current: -26.62
-26.62
12.66
ROE % -15.27
PRGO's ROE % is ranked lower than
79% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. PRGO: -15.27 )
Ranked among companies with meaningful ROE % only.
PRGO' s ROE % Range Over the Past 10 Years
Min: -15.27  Med: 15.81 Max: 25.88
Current: -15.27
-15.27
25.88
ROA % -7.84
PRGO's ROA % is ranked lower than
77% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. PRGO: -7.84 )
Ranked among companies with meaningful ROA % only.
PRGO' s ROA % Range Over the Past 10 Years
Min: -7.84  Med: 5.89 Max: 11.14
Current: -7.84
-7.84
11.14
ROC (Joel Greenblatt) % -91.68
PRGO's ROC (Joel Greenblatt) % is ranked lower than
82% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. PRGO: -91.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRGO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -91.68  Med: 36.1 Max: 53.06
Current: -91.68
-91.68
53.06
3-Year Revenue Growth Rate -0.80
PRGO's 3-Year Revenue Growth Rate is ranked lower than
72% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. PRGO: -0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRGO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.5  Med: 6.9 Max: 17.5
Current: -0.8
-5.5
17.5
3-Year EBITDA Growth Rate 7.40
PRGO's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. PRGO: 7.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRGO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.9  Med: 22.45 Max: 40
Current: 7.4
-24.9
40
3-Year EPS without NRI Growth Rate -39.60
PRGO's 3-Year EPS without NRI Growth Rate is ranked lower than
91% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. PRGO: -39.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRGO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.2  Med: 25.15 Max: 210.7
Current: -39.6
-66.2
210.7
» PRGO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PRGO Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 877,730 sh (New)
First Pacific Advisors 32,600 sh (New)
George Soros 6,400 sh (New)
Jerome Dodson 130,000 sh (+44.44%)
Ken Fisher 265,942 sh (+23.15%)
Keeley Asset Management Corp 26,348 sh (+6.56%)
Ruane Cunniff 1,461,985 sh (+1.03%)
Robert Bruce 9,926 sh (unchged)
Vanguard Health Care Fund Sold Out
Jim Simons Sold Out
Eric Mindich Sold Out
Louis Moore Bacon Sold Out
John Paulson 2,639,300 sh (-0.85%)
David Rolfe 2,077,826 sh (-1.67%)
Ron Baron 113,215 sh (-56.65%)
Paul Tudor Jones 2,100 sh (-67.19%)
Paul Singer 2,000 sh (-98.88%)
» More
Q2 2016

PRGO Guru Trades in Q2 2016

Jana Partners 481,077 sh (New)
Joel Greenblatt 19,855 sh (New)
David Einhorn 527,834 sh (New)
Murray Stahl 10,629 sh (New)
Manning & Napier Advisors, Inc 2,263,634 sh (+157.90%)
George Soros 10,800 sh (+68.75%)
Ken Fisher 339,967 sh (+27.84%)
Jerome Dodson 135,750 sh (+4.42%)
Robert Bruce 9,926 sh (unchged)
First Pacific Advisors Sold Out
Keeley Asset Management Corp Sold Out
David Rolfe Sold Out
Paul Singer Sold Out
Ron Baron Sold Out
Paul Tudor Jones Sold Out
Ruane Cunniff 1,315,805 sh (-10.00%)
John Paulson 12,500 sh (-99.53%)
» More
Q3 2016

PRGO Guru Trades in Q3 2016

Jim Simons 285,308 sh (New)
Ken Fisher 529,719 sh (+55.81%)
Manning & Napier Advisors, Inc 2,608,714 sh (+15.24%)
Ruane Cunniff 1,479,353 sh (+12.43%)
Robert Bruce 9,926 sh (unchged)
Jerome Dodson Sold Out
Jana Partners Sold Out
David Einhorn Sold Out
John Paulson Sold Out
George Soros Sold Out
Joel Greenblatt Sold Out
Murray Stahl 10,302 sh (-3.08%)
» More
Q4 2016

PRGO Guru Trades in Q4 2016

First Pacific Advisors 1,297,550 sh (New)
George Soros 5,400 sh (New)
Paul Tudor Jones 4,724 sh (New)
Joel Greenblatt 9,138 sh (New)
Jim Simons 628,508 sh (+120.29%)
Robert Bruce 9,926 sh (unchged)
Manning & Napier Advisors, Inc 2,571,194 sh (-1.44%)
Murray Stahl 10,043 sh (-2.51%)
Ken Fisher 514,718 sh (-2.83%)
Ruane Cunniff 1,315,276 sh (-11.09%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:PIG.Germany, PRGO.Israel,
Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates four segments: consumer health care, branded consumer healthcare, prescription pharmaceuticals, and active pharmaceutical ingredients. In the U.S., Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 43% of the company's revenue will come from outside the U.S.

Guru Investment Theses on Perrigo Co PLC

Jerome Dodson Comments on Perrigo - Jan 25, 2017

The Fund’s weakest performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock plummeted 42.5%, from $144.70 to $83.23, cutting 103 basis points from the Fund’s return. The shares sank in April after longtime CEO Joe Papa resigned to become the CEO of Valeant Pharmaceuticals. The stock continued to move lower throughout the year as the company cut its earnings guidance three times, from nearly $10 per share to just $7. The business underperformed due to declining prescription generic drug prices and soft growth from Omega, Perrigo’s European business. We sold our position during the year due to our concerns that the prescription generic pricing environment would get worse and that it would take longer than expected to fix Omega.



From the Parnassus Fund fourth quarter 2016 commentary.



Check out Jerome Dodson latest stock trades

Jerome Dodson Comments on Perrigo - Nov 01, 2016

We sold Perrigo (NYSE:PRGO), a producer of store-brand generic drugs, due to our concerns that the generic pricing environment would get worse and that it would take longer than expected to improve the company’s European platform. Additionally, we sold credit card issuer American Express, because we believe its moat is narrowing. Intense competition for the company’s affluent cardholders is pushing up rewards costs and marketing expenses, thereby lowering the company’s return on capital.

From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third-quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Keeley Funds Comment on Perrigo Co. - Aug 03, 2016

Perrigo Co. (NYSE:PRGO) was the Fund’s leading detractor this quarter. The stock price dropped over 22% and cost the Fund 62 basis points in performance. The company focuses on the production of over-the-counter consumer goods and specialty pharmaceutical products. The stock price dropped after the former CEO departed to join Valeant Pharmaceuticals and the Board of Directors named a new CEO. The new CEO promptly reduced guidance, causing an increase in skepticism about management’s ability to integrate a recent European acquisition.



From Keeley Funds' All Cap Value Fund second quarter commentary.



Check out John Keeley latest stock trades

Jerome Dodson Comments on Perrigo - Jul 26, 2016

Four companies each contributed 20 basis points or more to the Fund’s return this quarter, but six subtracted 20 basis points or more from the return. Our worst performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock sank 29.1% from $127.93 to $90.67, cutting 69 basis points from the Fund’s return. Shares plummeted in April after longtime CEO Joe Papa resigned to become the CEO at Valeant Pharmaceuticals, and Perrigo lowered its 2016 guidance for the second time this year. The business has underperformed due to declining generic drug prices and weak growth from Omega, Perrigo’s European business. While we think John Hendrickson, Perrigo’s new CEO, is the right person for the job given his strong operational background, we’re continuing to monitor the drug pricing environment.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

During the quarter, a surprising decline in Perrigo (NYSE:PRGO)’s normally staid generic prescription (Rx) business had the Company reduce full-year guidance by almost 15% in a late-April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of disconcerting data points, we decided it prudent to liquidate our Perrigo stake.

We think that, at its core, Perrigo’s U.S. private label over-the-counter (OTC) business is intrinsically attractive, with nearly 70% market share and long-tailed revenue streams similar to that of a consumer staple. Private-label OTC was about 50% of the Company’s calendar 2015 revenue, and nearly 40% of consolidated operating profitability.

Another third of Perrigo’s profits was derived from their generic Rx business which we believed, until recently, was relatively defensible. We had seen that Perrigo’s strategy in generic Rx was to target drugs that had small addressable markets (often less than $50 million per year sales), but a good probability of eventually becoming approved for OTC. We hypothesized that Perrigo’s rivals were slow to copy Perrigo generic drugs either because the addressable market was not big enough, and/or because margins on OTC are dramatically lower than Rx, particularly for sub-scale OTC manufacturers. (Private-label OTC manufacturing, marketing, and distribution support capabilities are substantially different from prescription). In other words, we saw Perrigo’s substantial scale in private-label OTC as enabling the Company to realize unique economics in other parts of their business, namely generic Rx. Therefore, it was surprising to us when the Company cut its own guidance for this unit by double-digits and then offered little in the way of an outlook, despite having provided a steady outlook just a few months ago.

Further, Perrigo’s relatively new BCH platform continued to underperform. The company expended almost $4.5 billion in shareholder capital to acquire BCH’s core asset, Omega Pharmaceutical, in early 2015. We think this business will be ineffective as a growth platform, despite management’s previous optimism. The Company has commented that the highly entrepreneurial culture of Omega has made it difficult to scale this business through further bolt-on acquisitions. The scaling of acquisitions has been a key component of Perrigo’s long-term growth strategy, so we would not be surprised if there are more examples of unrealized value- destruction embedded in the Omega acquisition.

Finally, Mr. Joe Papa, now former CEO of Perrigo, abruptly exited the Company in late April.
 Mr. Papa’s exit came after having spent countless hours and money, with the Board of Directors’ encouragement and unanimous approval, fending off Mylan’s hostile bid on the basis of the following: Perrigo’s stock being undervalued, Mylan’s poor corporate governance record, and the risk of dis-synergies. We now find shares trading at about half the supposedly undervalued bid price; Mr. Papa’s departure to run a company with one of the worst corporate governance track records around, dis-synergies from the Omega acquisition; and a materially weakened generic Rx franchise. Importantly, we think that execution missteps are expected over the long term and therefore manageable (if only because we can handicap those hiccups by building in a valuation cushion). However, we do not invest in Companies that are not forthcoming with their investor base. We question the credibility of Perrigo’s remaining management team, as well as the Board of Directors. In our experience, fortunately, this has been thankfully rare.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Perrigo - Jul 13, 2016

Perrigo (NYSE:PRGO) detracted –1.04% from the composite's absolute performance. A surprising decline in Perrigo’s normally staid generic prescription (Rx) business had the company reduce full-year guidance by almost 15% in a late April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of data points, we decided it prudent to liquidate our Perrigo stake.

From David Rolfe (Trades, Portfolio)'s second quarter 2016 Wedgewood Partners Client Letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Perrigo - Apr 15, 2016

Perrigo (NYSE:PRGO)

Perrigo was a bottom performance contributor in the quarter, as the company reported a miss in its Branded Consumer Healthcare (BCH) segment. Management attributed the miss to execution issues and dedicated themselves to solving these problems over the coming quarters. We are willing to be patient; in the meantime, as we think that Perrigo’s core, private label OTC business is unique and should remain a healthy and sustainable source of internal capital.

Perrigo’s BCH segment was established after closing on the acquisition of Omega Pharma (Belgium) in March 2015. Mylan’s hostile bid for Perrigo was launched a few weeks later, and did not conclude until mid-November. We think that Perrigo’s BCH execution issues are understandable (if not predictable), as management was admittedly distracted by fending off Mylan’s hostile bid for the Company during much of 2015. Over the next several quarters, we expect BCH to post improved results, as it is better integrated with Perrigo’s corporate planning cycle.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners 1st Quarter 2016 Client Letter.

Check out David Rolfe latest stock trades

Baron Funds Comments on Perrigo Company Plc - Jan 26, 2016

We re-established an investment in Perrigo Company Plc (NYSE:PRGO) during the quarter. Perrigo is a leading global over-the-counter (OTC) consumer goods and specialty pharmaceutical manufacturer. The company is the world’s largest manufacturer of store brand OTC health care products (such as store brand ibuprofen, the active ingredient in Advil), which are sold in virtually all leading U.S. drug retailers, including Walgreens and CVS. We previously owned Perrigo in the Fund. In early 2015, the company became the subject of a hostile takeover bid by Mylan N.V., a large manufacturer of generic pharmaceuticals. After Perrigo shareholders rejected Mylan’s proposal, Perrigo’s stock fell to a price that we believed was attractive in light of the company’s growth potential, competitive advantages and impressive management team.



We think Perrigo can generate sustainable mid-to-high single digit organic revenue growth, driven by a trend favoring store brand OTC drugs over national brands. Perrigo management estimates its business saves consumers more than $7.5 billion annually in their health care spending ($1 savings for every person in the world). This is because store brand OTC drugs are comparable in quality and effectiveness to the national brands but cost significantly less. Store brand OTC drugs also generate higher gross margins for retailers.



We think Perrigo’s business should also benefit as more prescription drugs move to OTC status. This trend is being driven by branded drug manufacturers seeking to capture ongoing product sales after the products lose patent protection. Perrigo has dominant market share in the store brand OTC drug business. We believe the company’s competitive advantages include long-standing customer relationships, low cost manufacturing and an ability to mass customize thousands of products and support retailers in marketing their store brands.



Perrigo’s management team has a strong record of creating shareholder value. They have a disciplined approach to deploying capital with a focus on meeting return on invested capital hurdles. We think management will continue to pursue acquisitions which should add to the company’s growth. These acquisitions could include products that Perrigo could add to its distribution network at high incremental margin, products in new categories, or companies in new geographies. In addition, in its defense against the Mylan hostile takeover attempt, Perrigo management committed to several shareholder value creating initiatives that are expected to add to earnings over the next few years.



From Baron Funds' Baron Asset Fund commentary for fourth quarter 2015.



Check out Ron Baron latest stock trades

Wedgewood Partners Comments on Perrigo - Jan 18, 2016

Perrigo (NYSE:PRGO) is another position that we added to during the quarter. We had previously pared positions at materially higher levels after Mylan’s hostile bid for Perrigo became public information. Upon the recent expiration of the hostile offer, shares traded down to valuation levels not seen since 2008-2009, at which time we added back to our position. Management has guided to solid future growth, driven by the Company’s leading position in manufacturing and distributing private label over-the-counter (OTC) drugs to U.S. retailers, as well as its relatively new and rapidly expanding European OTC platform.



From Wedgewood Partners' fourth quarter 2015 client letter.



Check out David Rolfe latest stock trades

Keeley Mid-Cap Value Fund Comments on Perrigo Co. - Sep 17, 2015

Another strong contributor during the quarter was Perrigo Co. (NYSE:PRGO) which climbed over 11 percent and added 24 basis points of performance to the Fund. The generic drug maker entered into an agreement with GlaxoSmithKline PLC to acquire a portfolio of over-the-counter drugs. Perrigo has already make acquisitions in the OTC business and this deal should allow them to capture an even larger share of the significant OTC market in Europe.



From the Keeley Mid-Cap Value Fund Second Quarter 2015 Commentary.



Check out John Keeley latest stock trades

Top Ranked Articles about Perrigo Co PLC

Jerome Dodson Comments on Perrigo Guru stock highlight
The Fund’s weakest performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock plummeted 42.5%, from $144.70 to $83.23, cutting 103 basis points from the Fund’s return. The shares sank in April after longtime CEO Joe Papa resigned to become the CEO of Valeant Pharmaceuticals. The stock continued to move lower throughout the year as the company cut its earnings guidance three times, from nearly $10 per share to just $7. The business underperformed due to declining prescription generic drug prices and soft growth from Omega, Perrigo’s European business. We sold our position during the year due to our concerns that the prescription generic pricing environment would get worse and that it would take longer than expected to fix Omega. Read more...
Perrigo, Ralph Lauren Reach 3-Year Low Prices Stocks that have hit their historical low prices
Perrigo Co. PLC (NYSE:PRGO) reached $77.80 Read more...
Jerome Dodson Comments on Perrigo Guru stock highlight
We sold Perrigo (NYSE:PRGO), a producer of store-brand generic drugs, due to our concerns that the generic pricing environment would get worse and that it would take longer than expected to improve the company’s European platform. Additionally, we sold credit card issuer American Express, because we believe its moat is narrowing. Intense competition for the company’s affluent cardholders is pushing up rewards costs and marketing expenses, thereby lowering the company’s return on capital. Read more...
Keeley Funds Comment on Perrigo Co. Guru stock highlight
Perrigo Co. (NYSE:PRGO) was the Fund’s leading detractor this quarter. The stock price dropped over 22% and cost the Fund 62 basis points in performance. The company focuses on the production of over-the-counter consumer goods and specialty pharmaceutical products. The stock price dropped after the former CEO departed to join Valeant Pharmaceuticals and the Board of Directors named a new CEO. The new CEO promptly reduced guidance, causing an increase in skepticism about management’s ability to integrate a recent European acquisition. Read more...
Jerome Dodson Comments on Perrigo Guru stock highlight
Four companies each contributed 20 basis points or more to the Fund’s return this quarter, but six subtracted 20 basis points or more from the return. Our worst performer was Perrigo (NYSE:PRGO), the leading producer of store-brand generic drugs, as its stock sank 29.1% from $127.93 to $90.67, cutting 69 basis points from the Fund’s return. Shares plummeted in April after longtime CEO Joe Papa resigned to become the CEO at Valeant Pharmaceuticals, and Perrigo lowered its 2016 guidance for the second time this year. The business has underperformed due to declining generic drug prices and weak growth from Omega, Perrigo’s European business. While we think John Hendrickson, Perrigo’s new CEO, is the right person for the job given his strong operational background, we’re continuing to monitor the drug pricing environment.
Read more...
David Rolfe Comments on Perrigo Guru stock highlight
Perrigo (NYSE:PRGO) detracted –1.04% from the composite's absolute performance. A surprising decline in Perrigo’s normally staid generic prescription (Rx) business had the company reduce full-year guidance by almost 15% in a late April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of data points, we decided it prudent to liquidate our Perrigo stake. Read more...
David Rolfe Comments on Perrigo Guru stock highlight
During the quarter, a surprising decline in Perrigo (NYSE:PRGO)’s normally staid generic prescription (Rx) business had the Company reduce full-year guidance by almost 15% in a late-April pre-earnings release. In addition, the Company disclosed further write-downs and organizational changes in their nascent Branded Consumer Health (BCH) segment. Last, the Company announced the abrupt exit of long-time CEO, Joe Papa, who joined embattled Valeant Pharmaceutical. Immediately after this slew of disconcerting data points, we decided it prudent to liquidate our Perrigo stake. Read more...
Ackman to Testify About Valeant Before Senate Valeant names Joseph Papa of Perrigo as new CEO
Activist investor Bill Ackman (Trades, Portfolio) will testify before the Senate Special Committee on Aging Wednesday regarding his involvement with Valeant Pharmaceuticals (NYSE:VRX), along with outgoing CEO Michael Pearson, just a day after Joseph Papa of Perrigo (NYSE:PRGO) was announced as Pearson’s replacement. Read more...
David Rolfe Comments on Perrigo Guru stock highlight
Perrigo (NYSE:PRGO)

Perrigo was a bottom performance contributor in the quarter, as the company reported a miss in its Branded Consumer Healthcare (BCH) segment. Management attributed the miss to execution issues and dedicated themselves to solving these problems over the coming quarters. We are willing to be patient; in the meantime, as we think that Perrigo’s core, private label OTC business is unique and should remain a healthy and sustainable source of internal capital.

Perrigo’s BCH segment was established after closing on the acquisition of Omega Pharma (Belgium) in March 2015. Mylan’s hostile bid for Perrigo was launched a few weeks later, and did not conclude until mid-November. We think that Perrigo’s BCH execution issues are understandable (if not predictable), as management was admittedly distracted by fending off Mylan’s hostile bid for the Company during much of 2015. Over the next several quarters, we expect BCH to post improved results, as it is better Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 15.24
PRGO's Forward PE Ratio is ranked higher than
59% of the 109 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. PRGO: 15.24 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.12
PRGO's PB Ratio is ranked higher than
86% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. PRGO: 1.12 )
Ranked among companies with meaningful PB Ratio only.
PRGO' s PB Ratio Range Over the Past 10 Years
Min: 1.12  Med: 3.12 Max: 5.96
Current: 1.12
1.12
5.96
PS Ratio 1.69
PRGO's PS Ratio is ranked higher than
69% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PRGO: 1.69 )
Ranked among companies with meaningful PS Ratio only.
PRGO' s PS Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.56 Max: 6.17
Current: 1.69
0.95
6.17
Price-to-Free-Cash-Flow 12.56
PRGO's Price-to-Free-Cash-Flow is ranked higher than
74% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.25 vs. PRGO: 12.56 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRGO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.61  Med: 24.94 Max: 83.99
Current: 12.56
10.61
83.99
Price-to-Operating-Cash-Flow 10.81
PRGO's Price-to-Operating-Cash-Flow is ranked higher than
70% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. PRGO: 10.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRGO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.67  Med: 18.97 Max: 30.33
Current: 10.81
8.67
30.33
EV-to-EBIT -9.03
PRGO's EV-to-EBIT is ranked lower than
99.99% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.12 vs. PRGO: -9.03 )
Ranked among companies with meaningful EV-to-EBIT only.
PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -11.6  Med: 19.8 Max: 1435.5
Current: -9.03
-11.6
1435.5
EV-to-EBITDA -15.66
PRGO's EV-to-EBITDA is ranked lower than
99.99% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. PRGO: -15.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.2  Med: 15.4 Max: 36.5
Current: -15.66
-20.2
36.5
Shiller PE Ratio 50.96
PRGO's Shiller PE Ratio is ranked lower than
55% of the 164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.73 vs. PRGO: 50.96 )
Ranked among companies with meaningful Shiller PE Ratio only.
PRGO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 39.8  Med: 87.24 Max: 192.79
Current: 50.96
39.8
192.79
Current Ratio 1.71
PRGO's Current Ratio is ranked lower than
66% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. PRGO: 1.71 )
Ranked among companies with meaningful Current Ratio only.
PRGO' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.34 Max: 4.05
Current: 1.71
1.1
4.05
Quick Ratio 1.13
PRGO's Quick Ratio is ranked lower than
71% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. PRGO: 1.13 )
Ranked among companies with meaningful Quick Ratio only.
PRGO' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.32 Max: 3.56
Current: 1.13
0.76
3.56
Days Inventory 91.67
PRGO's Days Inventory is ranked higher than
62% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. PRGO: 91.67 )
Ranked among companies with meaningful Days Inventory only.
PRGO' s Days Inventory Range Over the Past 10 Years
Min: 91.67  Med: 99.36 Max: 108.46
Current: 91.67
91.67
108.46
Days Sales Outstanding 73.03
PRGO's Days Sales Outstanding is ranked higher than
53% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. PRGO: 73.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.9  Med: 66.47 Max: 101.65
Current: 73.03
57.9
101.65
Days Payable 53.15
PRGO's Days Payable is ranked lower than
66% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. PRGO: 53.15 )
Ranked among companies with meaningful Days Payable only.
PRGO' s Days Payable Range Over the Past 10 Years
Min: 50.89  Med: 65.91 Max: 94.36
Current: 53.15
50.89
94.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.88
PRGO's Dividend Yield % is ranked lower than
71% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. PRGO: 0.88 )
Ranked among companies with meaningful Dividend Yield % only.
PRGO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.39 Max: 1.14
Current: 0.88
0.22
1.14
Dividend Payout Ratio 0.49
PRGO's Dividend Payout Ratio is ranked lower than
66% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. PRGO: 0.49 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PRGO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.14 Max: 0.5
Current: 0.49
0.07
0.5
3-Year Dividend Growth Rate 14.10
PRGO's 3-Year Dividend Growth Rate is ranked higher than
61% of the 286 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. PRGO: 14.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PRGO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.6 Max: 49.8
Current: 14.1
0
49.8
Forward Dividend Yield % 0.93
PRGO's Forward Dividend Yield % is ranked lower than
72% of the 646 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. PRGO: 0.93 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.64
PRGO's 5-Year Yield-on-Cost % is ranked lower than
60% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.19 vs. PRGO: 1.64 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PRGO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.41  Med: 0.73 Max: 2.13
Current: 1.64
0.41
2.13
3-Year Average Share Buyback Ratio -16.10
PRGO's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. PRGO: -16.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.1  Med: 0.2 Max: 1.9
Current: -16.1
-16.1
1.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.76
PRGO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
92% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. PRGO: 0.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRGO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.59 Max: 2.42
Current: 0.76
0.76
2.42
Price-to-Median-PS-Value 0.67
PRGO's Price-to-Median-PS-Value is ranked higher than
86% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. PRGO: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRGO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.58 Max: 2.17
Current: 0.67
0.23
2.17
Earnings Yield (Greenblatt) % -11.09
PRGO's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. PRGO: -11.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRGO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.1  Med: 5 Max: 8.5
Current: -11.09
-11.1
8.5
Forward Rate of Return (Yacktman) % 7.62
PRGO's Forward Rate of Return (Yacktman) % is ranked lower than
55% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.75 vs. PRGO: 7.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRGO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.8  Med: 12.8 Max: 35.8
Current: 7.62
1.8
35.8

More Statistics

Revenue (TTM) (Mil) $5,644
EPS (TTM) $ -10.48
Beta0.67
Short Percentage of Float6.14%
52-Week Range $66.86 - 133.53
Shares Outstanding (Mil)143.37

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 5,495 4,875 5,032 5,184
EPS ($) 7.22 4.82 5.56 5.67
EPS without NRI ($) 7.22 4.82 5.56 5.67
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.92%
Dividends per Share ($) 0.56 0.42 0.52 0.77
» More Articles for PRGO

Headlines

Articles On GuruFocus.com
First Pacific Advisors Buys Alcoa, Baidu,Yahoo Mar 03 2017 
Big Money Still Long Valeant Feb 28 2017 
Jerome Dodson Comments on Perrigo Jan 25 2017 
Jerome Dodson's Parnassus Fund 4th Quarter Commentary Jan 26 2017 
Perrigo, Ralph Lauren Reach 3-Year Low Prices Jan 14 2017 
Jerome Dodson Comments on Perrigo Nov 01 2016 
Jerome Dodson Goes 2 for 2 in 3rd Quarter Oct 17 2016 
5 of the Worst Stocks to Invest In Aug 18 2016 
Keeley Funds Comment on Perrigo Co. Aug 03 2016 
KEELEY All Cap Value Fund 2nd Quarter Commentary Aug 03 2016 

More From Other Websites
PERRIGO CO PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial... Mar 29 2017
Perrigo Completes Divestiture Of Tysabri® Royalty Stream For Up To $2.85 Billion Mar 27 2017
Lifshitz & Miller LLP Announces Investigation of Aratana Therapeutics, Inc., FXCM Inc., Innocoll... Mar 24 2017
Starboard Value's Jeff Smith Is Top Activist for Naming New Board Members Mar 23 2017
Moody's: Perrigo Filing Delay a "Credit Negative" Mar 20 2017
Perrigo Company plc -- Moody's: Perrigo's delayed 10-K filing is credit negative Mar 20 2017
PERRIGO CO PLC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Mar 17 2017
PERRIGO CO PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Mar 16 2017
Perrigo Provides Update On 2016 Form 10-K Filing Mar 16 2017
Perrigo Launches First to Market OTC Equivalent of Rogaine Mar 09 2017
RPI Finance Trust -- Moody's confirms RPI Finance Trust at Baa2; negative outlook Mar 09 2017
Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent To Women's Rogaine® Foam Mar 08 2017
Perrigo Provides 2016 Form 10-K Update Mar 07 2017
Pharma, Biotech Stocks Fall on Trump Tweets, GOP Health Care Plan Mar 07 2017
Perrigo Company PLC (PRGO) Becomes The Latest Pharma Investigated Over Price Fixing Mar 06 2017
Perrigo Joins Firms With Generic Drugs Under U.S. Glare Mar 03 2017
Perrigo Company PLC (PRGO) Drug Gets FDA Approval Mar 02 2017
Perrigo Company PLC (PRGO) Sells Rights To Tysabri Mar 01 2017
Five Companies to Benefit from Activist Starboard Value’s Involvement in 2017 Mar 01 2017
Pawar Law Group Announces Investigation of Securities Claims Against Perrigo Company plc - PRGO Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)